Vascular smooth muscle cells (VSMCs) are the main cellular component in the arterial wall, and abnormal proliferation of VSMCs plays a central role in the pathogenesis of
atherosclerosis and restenosis after angioplasty, and possibly in the development of
hypertension.
Pterostilbene, a natural dimethylated analog of
resveratrol, is known to have diverse pharmacological activities including anti-
cancer, anti-
inflammation and
anti-oxidant activities. The present study was designed to investigate the effects of
pterostilbene on
platelet-derived growth factor (
PDGF)-BB-induced VSMCs proliferation as well as the molecular mechanisms of the antiproliferative effects. The cell growth of VSMCs was determined by cell counting and [(3)H]
thymidine incorporation assays.
Pterostilbene significantly inhibited the
DNA synthesis and proliferation of
PDGF-BB-stimulated VSMCs in a concentration-dependent manner. The inhibition percentages of
pterostilbene at 1, 3 and 5microM to VSMCs proliferation were 68.5, 80.7 and 94.6%, respectively. The
DNA synthesis of
pterostilbene at 1, 3 and 5microM in VSMCs was inhibited by 47.4, 76.7 and 100%, respectively.
Pterostilbene inhibited the
PDGF-BB-stimulated phosphorylation of Akt
kinase. However,
pterostilbene did not change the expression of extracellular signal-related
kinase (ERK) 1/2, PLCgamma1,
phosphatidylinositol (
PI)3 kinase and PDGF-Rbeta phosphorylation. In addition,
pterostilbene down-regulated the cell cycle-related
proteins including the expression of
cyclin-dependent kinase (CDK) 2,
cyclin E, CDK4,
cyclin D1,
retinoblastoma (Rb)
proteins and proliferative cell
nuclear antigen (
PCNA). These findings suggest that the inhibition of
pterostilbene to the cell proliferation and
DNA synthesis of
PDGF-BB-stimulated VSMCs may be mediated by the suppression of Akt
kinase. Furthermore,
pterostilbene may be a potential anti-proliferative agent for the treatment of
atherosclerosis and angioplasty restenosis.